ISPAD GUIDELINES
ISPAD Clinical Practice Consensus Guidelines 2022: Microvascular and macrovascular complications in children and adolescents with diabetes
Petter Bjornstad,
Allison Dart,
Kim C. Donaghue,
Axel Dost,
Eva L. Feldman,
Gavin S. Tan,
R. Paul Wadwa,
Bedowra Zabeen,
M. Loredana Marcovecchio,
Corresponding Author
Petter Bjornstad
Section of Endocrinology, Department of Pediatrics, Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Denver, Colorado, USA
Correspondence
Petter Bjornstad, Section of Endocrinology, Department of Pediatrics, Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, 13123 E 16th Ave, Box 465, Aurora, CO 80045-7106, USA.
Email: [email protected]
Search for more papers by this authorAllison Dart
Department of Pediatrics, Divison of Nephrology, Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada
Search for more papers by this authorKim C. Donaghue
Department of Pediatrics, Division of Endocrinology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia
Discipline of Child and Adolescent Health, University of Sydney, Sydney, New South Wales, Australia
Search for more papers by this authorAxel Dost
Department of Pediatrics, Division of Endocrinology, Jena University Hospital, Jena, Germany
Search for more papers by this authorEva L. Feldman
Department of Medicine, Division of Neurology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
Search for more papers by this authorGavin S. Tan
Singapore Eye Research Institute, Singapore National Eye Center, Singapore
Department of Ophthalmology and Visual Sciences, Duke-NUS Medical School, National University of Singapore, Singapore
Search for more papers by this authorR. Paul Wadwa
Section of Endocrinology, Department of Pediatrics, Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Denver, Colorado, USA
Search for more papers by this authorBedowra Zabeen
Department of Paediatrics and Changing Diabetes in Children Program, Bangladesh Institute of Research and Rehabilitation in Diabetes Endocrine and Metabolic Disorders, Dhaka, Bangladesh
Search for more papers by this authorM. Loredana Marcovecchio
Department of Paediatrics, University of Cambridge, and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Search for more papers by this authorPetter Bjornstad,
Allison Dart,
Kim C. Donaghue,
Axel Dost,
Eva L. Feldman,
Gavin S. Tan,
R. Paul Wadwa,
Bedowra Zabeen,
M. Loredana Marcovecchio,
Corresponding Author
Petter Bjornstad
Section of Endocrinology, Department of Pediatrics, Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Denver, Colorado, USA
Correspondence
Petter Bjornstad, Section of Endocrinology, Department of Pediatrics, Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, 13123 E 16th Ave, Box 465, Aurora, CO 80045-7106, USA.
Email: [email protected]
Search for more papers by this authorAllison Dart
Department of Pediatrics, Divison of Nephrology, Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada
Search for more papers by this authorKim C. Donaghue
Department of Pediatrics, Division of Endocrinology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia
Discipline of Child and Adolescent Health, University of Sydney, Sydney, New South Wales, Australia
Search for more papers by this authorAxel Dost
Department of Pediatrics, Division of Endocrinology, Jena University Hospital, Jena, Germany
Search for more papers by this authorEva L. Feldman
Department of Medicine, Division of Neurology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
Search for more papers by this authorGavin S. Tan
Singapore Eye Research Institute, Singapore National Eye Center, Singapore
Department of Ophthalmology and Visual Sciences, Duke-NUS Medical School, National University of Singapore, Singapore
Search for more papers by this authorR. Paul Wadwa
Section of Endocrinology, Department of Pediatrics, Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Denver, Colorado, USA
Search for more papers by this authorBedowra Zabeen
Department of Paediatrics and Changing Diabetes in Children Program, Bangladesh Institute of Research and Rehabilitation in Diabetes Endocrine and Metabolic Disorders, Dhaka, Bangladesh
Search for more papers by this authorM. Loredana Marcovecchio
Department of Paediatrics, University of Cambridge, and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Search for more papers by this author
CONFLICT OF INTEREST
PB has acted as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Sanofi, Novo Nordisk and Horizon Pharma. PB serves on the advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk and XORTX. RPW has research support from Dexcom, Eli Lilly & Co and Tandem Diabetes Care. RPW has served on an advisory board for Dompe.
REFERENCES
- 1 Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. J Pediatr. 1994; 125(2): 177-188. doi:10.1016/s0022-3476(94)70190-3
- 2Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med. 1994; 330(1): 15-18. doi:10.1056/nejm199401063300103
- 3Downie E, Craig ME, Hing S, Cusumano J, Chan AK, Donaghue KC. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control. Diabetes Care. 2011; 34(11): 2368-2373. doi:10.2337/dc11-0102
- 4Majaliwa ES, Munubhi E, Ramaiya K, et al. Survey on acute and chronic complications in children and adolescents with type 1 diabetes at Muhimbili National Hospital in Dar es Salaam, Tanzania. Diabetes Care. 2007; 30(9): 2187-2192. doi:10.2337/dc07-0594
- 5Urbina EM, Isom S, Bell RA, et al. Burden of cardiovascular risk factors over time and arterial stiffness in youth with type 1 diabetes mellitus: the SEARCH for diabetes in youth study. J Am Heart Assoc. 2019; 8(13):e010150. doi:10.1161/JAHA.118.010150
- 6Sandahl K, Nielsen LB, Svensson J, et al. Increased mortality in a Danish cohort of young people with type 1 diabetes mellitus followed for 24 years. Diabetic Med. 2017; 34(3): 380-386. doi:10.1111/dme.13124
- 7Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017; 376(15): 1419-1429. doi:10.1056/NEJMoa1610187
- 8Tönnies T, Saydah S, Isom S, et al. 156-OR: projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2060. Diabetes. 2021; 70(Supplement 1). doi:10.2337/db21-156-OR
10.2337/db21?156?OR Google Scholar
- 9 RISE Consortium, RISE Consortium Investigators. Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on beta-cell function: comparison of responses In youth and adults. Diabetes. 2019; 68(8): 1670-1680. doi:10.2337/db19-0299
- 10 RISE Consortium. Impact of insulin and metformin versus metformin alone on beta-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care. 2018; 41(8): 1717-1725. doi:10.2337/dc18-0787
- 11Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and Young adulthood. Jama. 2017; 317(8): 825-835. doi:10.1001/jama.2017.0686
- 12 TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the today clinical trial. Randomized controlled trial research support, N.I.H., extramural. Diabetes Care. 2013; 36(6): 1735-1741. doi:10.2337/dc12-2420
- 13Al-Saeed AH, Constantino MI, Molyneaux L, et al. An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes. Diabetes Care. 2016; 39(5): 823-829. doi:10.2337/dc15-0991
- 14 RISE Consortium. Lack of durable improvements in beta-cell function following withdrawal of pharmacological interventions in adults with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care. 2019; 42(9): 1742-1751. doi:10.2337/dc19-0556
- 15Barrett T, Jalaludin MY, Turan S, Hafez M, Shehadeh N. Novo Nordisk pediatric type 2 diabetes global expert P. rapid progression of type 2 diabetes and related complications in children and young people-a literature review. Pediatr Diabetes. 2020; 21(2): 158-172. doi:10.1111/pedi.12953
- 16 Today Study Group, Bjornstad P, Drews KL, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021; 385(5): 416-426. doi:10.1056/NEJMoa2100165
- 17Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 977-986. doi:10.1056/nejm199309303291401
- 18Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342(6): 381-389. doi:10.1056/nejm200002103420603
- 19Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (EDIC) study. Jama. 2003; 290(16): 2159-2167. doi:10.1001/jama.290.16.2159
- 20White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010; 59(5): 1244-1253. doi:10.2337/db09-1216
- 21Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25): 2643-2653. doi:10.1056/NEJMoa052187
- 22Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care. 2016; 39(5): 686-693. doi:10.2337/dc15-1990
- 23Sauder KA, Stafford JM, Mayer-Davis EJ, et al. Co-occurrence of early diabetes-related complications in adolescents and young adults with type 1 diabetes: an observational cohort study. Lancet Child Adolesc Health. 2019; 3(1): 35-43. doi:10.1016/S2352-4642(18)30309-2
- 24Lind M, Pivodic A, Svensson AM, Olafsdottir AF, Wedel H, Ludvigsson J. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ. 2019; 366:l4894. doi:10.1136/bmj.l4894
- 25Amin R, Widmer B, Prevost AT, et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ. 2008; 336(7646): 697-701. doi:10.1136/bmj.39478.378241.BE
- 26Benitez-Aguirre P, Craig ME, Cass HG, et al. Sex differences in retinal microvasculature through puberty in type 1 diabetes: are girls at greater risk of diabetic microvascular complications? Invest Ophthalmol Vis Sci. 2014; 56(1): 571-577. doi:10.1167/iovs.14-15147
- 27Donaghue KC, Fairchild JM, Craig ME, et al. Do all prepubertal years of diabetes duration contribute equally to diabetes complications? Diabetes Care. 2003; 26(4): 1224-1229. doi:10.2337/diacare.26.4.1224
- 28Cho YH, Craig ME, Donaghue KC. Puberty as an accelerator for diabetes complications. Pediatr Diabetes. 2014; 15(1): 18-26. doi:10.1111/pedi.12112
- 29Donaghue KC, Craig ME, Chan AK, et al. Prevalence of diabetes complications 6 years after diagnosis in an incident cohort of childhood diabetes. Diabetic Med. 2005; 22(6): 711-718. doi:10.1111/j.1464-5491.2005.01527.x
- 30Vistisen D, Andersen GS, Hulman A, et al. A validated prediction model for end-stage kidney disease in type 1 diabetes. Diabetes Care. 2021; 44(4): 901-907. doi:10.2337/dc20-2586
- 31Margeirsdottir HD, Larsen JR, Brunborg C, Overby NC, Dahl-Jørgensen K. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. Diabetologia. 2008; 51(4): 554-561. doi:10.1007/s00125-007-0921-8
- 32Wood JR, Miller KM, Maahs DM, et al. Most youth with type 1 diabetes in the T1D exchange clinic registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care. 2013; 36(7): 2035-2037. doi:10.2337/dc12-1959
- 33Jones S, Khanolkar AR, Gevers E, Stephenson T, Amin R. Cardiovascular risk factors from diagnosis in children with type 1 diabetes mellitus: a longitudinal cohort study. BMJ Open Diabetes Res Care. 2019; 7(1):e000625. doi:10.1136/bmjdrc-2018-000625
- 34Kim G, Divers J, Fino NF, et al. Trends in prevalence of cardiovascular risk factors from 2002 to 2012 among youth early in the course of type 1 and type 2 diabetes. The SEARCH for diabetes in youth study. Pediatr Diabetes. 2019; 20(6): 693-701. doi:10.1111/pedi.12846
- 35Shah AS, Dabelea D, Talton JW, et al. Smoking and arterial stiffness in youth with type 1 diabetes: the SEARCH cardiovascular disease study. J Pediatr. 2014; 165(1): 110-116. doi:10.1016/j.jpeds.2014.02.024
- 36Gay EC, Cai Y, Gale SM, et al. Smokers with IDDM experience excess morbidity the Colorado IDDM Registry. Diabetes Care. 1992; 15(8): 947-952. doi:10.2337/diacare.15.8.947
- 37Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002; 347(11): 797-805. doi:10.1056/NEJMoa013410
- 38Marcovecchio ML, Dalton RN, Schwarze CP, et al. Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. Diabetologia. 2009; 52(6): 1173-1181. doi:10.1007/s00125-009-1327-6
- 39Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ. 2008; 337:a918. doi:10.1136/bmj.a918
- 40Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993; 16(2): 434-444. doi:10.2337/diacare.16.2.434
- 41Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial HOT Study Group. Lancet (London, England). 1998; 351(9118): 1755-1762. doi:10.1016/s0140-6736(98)04311-6
- 42Marcovecchio ML, Dalton RN, Prevost AT, et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care. 2009; 32(4): 658-663. doi:10.2337/dc08-1641
- 43Raile K, Galler A, Hofer S, et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care. 2007; 30(10): 2523-2528. doi:10.2337/dc07-0282
- 44Jenkins AJ, Lyons TJ, Zheng D, et al. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int. 2003; 64(3): 817-828. doi:10.1046/j.1523-1755.2003.00164.x
- 45Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989; 320(18): 1161-1165. doi:10.1056/nejm198905043201801
- 46Marcovecchio ML, Tossavainen PH, Acerini CL, et al. Maternal but not paternal association of ambulatory blood pressure with albumin excretion in young offspring with type 1 diabetes. Diabetes Care. 2010; 33(2): 366-371. doi:10.2337/dc09-1152
- 47Marcovecchio ML, Tossavainen PH, Owen K, et al. Clustering of cardio-metabolic risk factors in parents of adolescents with type 1 diabetes and microalbuminuria. Pediatr Diabetes. 2017; 18(8): 947-954. doi:10.1111/pedi.12515
- 48Stone ML, Craig ME, Chan AK, Lee JW, Verge CF, Donaghue KC. Natural history and risk factors for microalbuminuria in adolescents with type 1 diabetes: a longitudinal study. Diabetes Care. 2006; 29(9): 2072-2077. doi:10.2337/dc06-0239
- 49de Boer IH, Sibley SD, Kestenbaum B, et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol. 2007; 18(1): 235-243. doi:10.1681/ASN.2006040394
- 50Dorchy H, Claes C, Verougstraete C. Risk factors of developing proliferative retinopathy in type 1 diabetic patients: role of BMI. Diabetes Care. 2002; 25(4): 798-799. doi:10.2337/diacare.25.4.798
- 51De Block CE, De Leeuw IH, Van Gaal LF. Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care. 2005; 28(7): 1649-1655. doi:10.2337/diacare.28.7.1649
- 52Purnell JQ, Braffett BH, Zinman B, et al. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes Care. 2017; 40(12): 1756-1762. doi:10.2337/dc16-2523
- 53Tommerdahl KL, Baumgartner K, Schafer M, et al. Impact of obesity on measures of cardiovascular and kidney health in youth with type 1 diabetes as compared with youth with type 2 diabetes. Diabetes Care. 2021; 44(3): 795-803. doi:10.2337/dc20-1879
- 54Moy CS, Songer TJ, LaPorte RE, et al. Insulin-dependent diabetes mellitus, physical activity, and death. Am J Epidemiol. 1993; 137(1): 74-81. doi:10.1093/oxfordjournals.aje.a116604
- 55Pham-Short A, Donaghue KC, Ambler G, et al. Early elevation of albumin excretion rate is associated with poor gluten-free diet adherence in young people with coeliac disease and diabetes. Diabetic Med. 2014; 31(2): 208-212. doi:10.1111/dme.12329
- 56Rohrer TR, Wolf J, Liptay S, et al. Microvascular complications in childhood-onset type 1 diabetes and celiac disease: a multicenter longitudinal analysis of 56,514 patients from the German-Austrian DPV database. Diabetes Care. 2015; 38(5): 801-807. doi:10.2337/dc14-0683
- 57Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh epidemiology of diabetes complications study. Diabetologia. 2010; 53(11): 2312-2319. doi:10.1007/s00125-010-1860-3
- 58Groop PH, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009; 58(7): 1651-1658. doi:10.2337/db08-1543
- 59Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015; 313(1): 37-44. doi:10.1001/jama.2014.16425
- 60Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983; 32(Suppl 2): 64-78. doi:10.2337/diab.32.2.s64
- 61Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet (London, England). 1995; 346(8982): 1080-1084. doi:10.1016/s0140-6736(95)91747-0
- 62 Kidney disease: improving global outcomes diabetes work G. KDIGO 2020 clinical practice guideline for diabetes Management in Chronic Kidney Disease. Kidney Int. 2020; 98(4 S): S1-S115. doi:10.1016/j.kint.2020.06.019
- 63Colombo M, McGurnaghan SJ, Bell S, et al. Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. Diabetologia. 2020; 63(3): 636-647. doi:10.1007/s00125-019-05052-z
- 64Helve J, Sund R, Arffman M, et al. Incidence of end-stage renal disease in patients with type 1 diabetes. Diabetes Care. 2018; 41(3): 434-439. doi:10.2337/dc17-2364
- 65Costacou T, Orchard TJ. Cumulative kidney complication risk by 50 years of type 1 diabetes: the effects of sex, age, and calendar year at onset. Diabetes Care. 2018; 41(3): 426-433. doi:10.2337/dc17-1118
- 66Maahs DM, Snively BM, Bell RA, et al. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for diabetes in youth study. Diabetes Care. 2007; 30(10): 2593-2598. doi:10.2337/dc07-0450
- 67Kahkoska AR, Isom S, Divers J, et al. The early natural history of albuminuria in young adults with youth-onset type 1 and type 2 diabetes. J Diabetes Complications. 2018; 32(12): 1160-1168. doi:10.1016/j.jdiacomp.2018.09.018
- 68Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M. The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes. 2005; 54(7): 2164-2171. doi:10.2337/diabetes.54.7.2164
- 69Cioana M, Deng J, Hou M, et al. Prevalence of hypertension and albuminuria in pediatric type 2 diabetes: a systematic review and meta-analysis. JAMA Netw Open. 2021; 4(4):e216069. doi:10.1001/jamanetworkopen.2021.6069
- 70Wicklow BA, Sellers EAC, Sharma AK, et al. Association of Gestational Diabetes and Type 2 diabetes exposure In utero with the development of type 2 diabetes in first nations and non-first nations offspring. JAMA Pediatr. 2018; 172(8): 724-731. doi:10.1001/jamapediatrics.2018.1201
- 71Nelson RG, Morgenstern H, Bennett PH. Intrauterine diabetes exposure and the risk of renal disease in diabetic Pima Indians. Diabetes. 1998; 47(9): 1489-1493. doi:10.2337/diabetes.47.9.1489
- 72Huria T, Pitama SG, Beckert L, et al. Reported sources of health inequities in indigenous peoples with chronic kidney disease: a systematic review of quantitative studies. BMC Public Health. 2021; 21(1): 1447. doi:10.1186/s12889-021-11180-2
- 73Dart A. Sociodemographic determinants of chronic kidney disease in indigenous children. Pediatr Nephrol. 2022; 37(3): 547-553. doi:10.1007/s00467-021-05110-y
- 74Narva AS. The spectrum of kidney disease in American Indians. Kidney Int Suppl. 2003; 83: S3-S7. doi:10.1046/j.1523-1755.63.s83.2.x
10.1046/j.1523?1755.63.s83.2.x Google Scholar
- 75Fiorentino M, Bolignano D, Tesar V, et al. Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. Nephrol Dial Transplant. 2017; 32(1): 97-110. doi:10.1093/ndt/gfw070
- 76Sellers EA, Blydt-Hansen TD, Dean HJ, Gibson IW, Birk PE, Ogborn M. Macroalbuminuria and renal pathology in first nation youth with type 2 diabetes. Diabetes Care. 2009; 32(5): 786-790. doi:10.2337/dc08-1828
- 77Gorman D, Sochett E, Daneman D. The natural history of microalbuminuria in adolescents with type 1 diabetes. J Pediatr. 1999; 134(3): 333-337. doi:10.1016/s0022-3476(99)70459-2
- 78de Boer IH, Gao X, Cleary PA, et al. Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC study. Clin J Am Soc Nephrol CJASN. 2016; 11(11): 1969-1977. doi:10.2215/cjn.02870316
- 79Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (London, England). 2012; 380(9854): 1662-1673. doi:10.1016/s0140-6736(12)61350-6
- 80Schultz CJ, Neil HA, Dalton RN, Dunger DB. Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes. Diabetes Care. 2000; 23(12): 1811-1815. doi:10.2337/diacare.23.12.1811
- 81Cho YH, Craig ME, Hing S, et al. Microvascular complications assessment in adolescents with 2- to 5-yr duration of type 1 diabetes from 1990 to 2006. Pediatr Diabetes. 2011; 12: 682-689. doi:10.1111/j.1399-5448.2011.00762.x
- 82Zabeen B, Nahar J, Islam N, Azad K, Donaghue K. Risk factors associated with microalbuminuria in children and adolescents with diabetes in Bangladesh. Indian J Endocrinol metabol. 2018; 22(1): 85-88. doi:10.4103/ijem.IJEM_269_17
- 83Marcovecchio ML, Woodside J, Jones T, et al. Adolescent type 1 diabetes cardio-renal intervention trial (AdDIT): urinary screening and baseline biochemical and cardiovascular assessments. Diabetes Care. 2014; 37(3): 805-813. doi:10.2337/dc13-1634
- 84Marcovecchio ML, Chiesa ST, Armitage J, et al. Renal and cardiovascular risk according to tertiles of urinary albumin-to-creatinine ratio: the adolescent type 1 diabetes cardio-renal intervention trial (AdDIT). Diabetes Care. 2018; 41(9): 1963-1969. doi:10.2337/dc18-1125
- 85Benitez-Aguirre PZ, Marcovecchio ML, Chiesa ST, et al. Urinary albumin/creatinine ratio tertiles predict risk of diabetic retinopathy progression: a natural history study from the adolescent cardio-renal intervention trial (AdDIT) observational cohort. Diabetologia. 2022; 65(5): 872-878. doi:10.1007/s00125-022-05661-1
- 86Lambers Heerspink HJ, Gansevoort RT, Brenner BM, et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol. 2010; 21(8): 1355-1360. doi:10.1681/asn.2010010063
- 87Viberti G. Etiology and prognostic significance of albuminuria in diabetes. Diabetes Care. 1988; 11(10): 840-845. doi:10.2337/diacare.11.10.840
- 88Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984; 310(6): 356-360. doi:10.1056/nejm198402093100605
- 89Krolewski AS, Niewczas MA, Skupien J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care. 2014; 37(1): 226-234. doi:10.2337/dc13-0985
- 90Penno G, Russo E, Garofolo M, et al. Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. Diabetologia. 2017; 60(6): 1102-1113. doi:10.1007/s00125-017-4251-1
- 91Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1. Diabetes. 2003; 348(23): 2285-2293. doi:10.1056/NEJMoa021835
- 92Boettcher C, Utsch B, Galler A, et al. Estimated glomerular filtration rates calculated by new and old equations in children and adolescents with type 1 diabetes-what to do with the results? Front Endocrinol (Lausanne). 2020; 11: 52. doi:10.3389/fendo.2020.00052
- 93Pierce CB, Muñoz A, Ng DK, Warady BA, Furth SL, Schwartz GJ. Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int. 2021; 99(4): 948-956. doi:10.1016/j.kint.2020.10.047
- 94Gaebe K, White CA, Mahmud FH, et al. Evaluation of novel glomerular filtration rate estimation equations in adolescents and young adults with type 1 diabetes. J Diabetes Complications. 2022; 36(1):108081. doi:10.1016/j.jdiacomp.2021.108081
- 95Dart AB, McGavock J, Sharma A, Chateau D, Schwartz GJ, Blydt-Hansen T. Estimating glomerular filtration rate in youth with obesity and type 2 diabetes: the iCARE study equation. Pediatr Nephrol. 2019; 34(9): 1565-1574. doi:10.1007/s00467-019-04250-6
- 96Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation hypertension and diabetes Executive committees working group. Am J Kidney Dis. 2000; 36(3): 646-661. doi:10.1053/ajkd.2000.16225
- 97Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed). 1987; 294(6585): 1443-1447. doi:10.1136/bmj.294.6585.1443
- 98Andrésdóttir G, Jensen ML, Carstensen B, et al. Improved prognosis of diabetic nephropathy in type 1 diabetes. Kidney Int. 2015; 87(2): 417-426. doi:10.1038/ki.2014.206
- 99Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2012; 12:Cd004136. doi:10.1002/14651858.CD004136.pub3
- 100Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2005;(4):Cd004136. doi:10.1002/14651858.CD004136.pub2
- 101Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013; 347:f6008. doi:10.1136/bmj.f6008
- 102Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006; 2006(4):Cd006257. doi:10.1002/14651858.Cd006257
- 103Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009; 361(1): 40-51.
- 104Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016; 352: i438. doi:10.1136/bmj.i438
- 105Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001; 134(5): 370-379. doi:10.7326/0003-4819-134-5-200103060-00009
- 106Izzo JL Jr, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich). 2011; 13(9): 667-675. doi:10.1111/j.1751-7176.2011.00508.x
- 107Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004; 329(7470): 828. doi:10.1136/bmj.38237.585000.7C
- 108Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension (Dallas, Tex: 1979). 2012; 60(2): 444-450. doi:10.1161/hypertensionaha.112.196352
- 109Marcovecchio ML, Chiesa ST, Bond S, et al. ACE inhibitors and statins in adolescents with type 1 diabetes. N Engl J Med. 2017; 377(18): 1733-1745. doi:10.1056/NEJMoa1703518
- 110Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2020; 384: 129-139. doi:10.1056/NEJMoa2030186
- 111Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019; 7(11): 845-854. doi:10.1016/S2213-8587(19)30256-6
- 112Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017; 377(9): 839-848. doi:10.1056/NEJMoa1616011
- 113Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375(4): 323-334. doi:10.1056/NEJMoa1515920
- 114Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin epidemiologic study of diabetic retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008; 115(11): 1859-1868. doi:10.1016/j.ophtha.2008.08.023
- 115Donaghue KC, Wadwa RP, Dimeglio LA, et al. ISPAD clinical practice consensus guidelines 2014. Microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes. 2014; 15(Suppl 20): 257-269. doi:10.1111/pedi.12180
- 116Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003; 110(9): 1677-1682. doi:10.1016/s0161-6420(03)00475-5
- 117Wong TY, Cheung CM, Larsen M, Sharma S, Simó R. Diabetic retinopathy. Nat Rev Dis Primers. 2016; 2:16012. doi:10.1038/nrdp.2016.12
- 118LeCaire TJ, Palta M, Klein R, Klein BE, Cruickshanks KJ. Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin diabetes registry study and the Wisconsin epidemiologic study of diabetic retinopathy. Diabetes Care. 2013; 36(3): 631-637. doi:10.2337/dc12-0863
- 119Elgemai E, Zeriban N, Soliman S. Prevalence of diabetic retinopathy among children with type 1 diabetes mellitus treated by insulin. Delta J Opthalmol. 2018; 19(3): 196-200. doi:10.4103/djo.Djo_15_18
10.4103/djo.Djo_15_18 Google Scholar
- 120Ferm ML, DeSalvo DJ, Prichett LM, Sickler JK, Wolf RM, Channa R. Clinical and demographic factors associated with diabetic retinopathy among Young patients with diabetes. JAMA Netw Open. 2021; 4(9):e2126126. doi:10.1001/jamanetworkopen.2021.26126
- 121Zabeen B, Khaled MZ, Husain L, et al. Risk factors associated with retinopathy in young people with type 1 diabetes in Bangladesh. Endocrinol Diabetes Metabol. 2021; 4(2):e00197. doi:10.1002/edm2.197
- 122Bratina N, Auzanneau M, Birkebaek N, et al. Differences in retinopathy prevalence and associated risk factors across 11 countries in three continents: a cross-sectional study of 156,090 children and adolescents with type 1 diabetes. Pediatr Diabetes. 2022; 23: 1656-1664.
- 123Huo B, Steffen AT, Swan K, Sikes K, Weinzimer SA, Tamborlane WV. Clinical outcomes and cost-effectiveness of retinopathy screening in youth with type 1 diabetes. Diabetes Care. 2007; 30(2): 362-363. doi:10.2337/dc06-1824
- 124Geloneck MM, Forbes BJ, Shaffer J, Ying GS, Binenbaum G. Ocular complications in children with diabetes mellitus. Ophthalmology. 2015; 122(12): 2457-2464. doi:10.1016/j.ophtha.2015.07.010
- 125Beauchamp G, Boyle CT, Tamborlane WV, et al. Treatable diabetic retinopathy is extremely rare among pediatric T1D exchange clinic registry participants. Diabetes Care. 2016; 39(12): e218-e219. doi:10.2337/dc16-1691
- 126Wang SY, Andrews CA, Herman WH, Gardner TW, Stein JD. Incidence and risk factors for developing diabetic retinopathy among youths with type 1 or type 2 diabetes throughout the United States. Ophthalmology. 2017; 124(4): 424-430. doi:10.1016/j.ophtha.2016.10.031
- 127Wang SY, Andrews CA, Gardner TW, Wood M, Singer K, Stein JD. Ophthalmic screening patterns among youths with diabetes enrolled in a large US managed care network. JAMA Ophthalmol. 2017; 135(5): 432-438. doi:10.1001/jamaophthalmol.2017.0089
- 128Scanlon PH, Stratton IM, Bachmann MO, Jones C, Leese GP. Risk of diabetic retinopathy at first screen in children at 12 and 13 years of age. Diabet Med. 2016; 33(12): 1655-1658. doi:10.1111/dme.13263
- 129Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol (Chicago, Ill: 1960). 1998; 116(7): 874-886. doi:10.1001/archopht.116.7.874
10.1001/archopht.116.7.874 Google Scholar
- 130Daneman D, Drash AL, Lobes LA, Becker DJ, Baker LM, Travis LB. Progressive retinopathy with improved control in diabetic dwarfism (Mauriac's syndrome). Diabetes Care. 1981; 4(3): 360-365. doi:10.2337/diacare.4.3.360
- 131Axer-Siegel R, Hod M, Fink-Cohen S, et al. Diabetic retinopathy during pregnancy. Ophthalmology. 1996; 103(11): 1815-1819. doi:10.1016/s0161-6420(96)30421-1
- 132Best RM, Chakravarthy U. Diabetic retinopathy in pregnancy. Br J Ophthalmol. 1997; 81(3): 249-251. doi:10.1136/bjo.81.3.249
- 133Bragge P, Gruen RL, Chau M, Forbes A, Taylor HR. Screening for presence or absence of diabetic retinopathy: a meta-analysis. Arch Ophthalmol (Chicago, Ill: 1960). 2011; 129(4): 435-444. doi:10.1001/archophthalmol.2010.319
- 134Silva PS, Cavallerano JD, Haddad NM, et al. Peripheral lesions identified on Ultrawide field imaging predict increased risk of diabetic retinopathy progression over 4 years. Ophthalmology. 2015; 122(5): 949-956. doi:10.1016/j.ophtha.2015.01.008
- 135DSW T, GSW T, Agrawal R, et al. Optical coherence tomographic angiography in type 2 diabetes and diabetic retinopathy. JAMA Ophthalmol. 2017; 135(4): 306-312. doi:10.1001/jamaophthalmol.2016.5877
- 136Chua J, Sim R, Tan B, et al. Optical coherence tomography angiography in diabetes and diabetic retinopathy. J Clin Med. 2020; 9(6):1723. doi:10.3390/jcm9061723
- 137Allen DW, Liew G, Cho YH, et al. Thirty-year time trends in diabetic retinopathy and macular edema in youth with type 1 diabetes. Diabetes Care. 2022; 45: 2247-2254. doi:10.2337/dc21-1652
- 138Graves LE, Pryke AF, Cho YH, et al. Sight-threatening retinopathy in nine adolescents with early onset type 1 diabetes. Pediatr Diabetes. 2021; 22(8): 1129-1134. doi:10.1111/pedi.13265
- 139 DCCT EDIC Research Group, Nathan DM, Bebu I, et al. Frequency of evidence-based screening for retinopathy in type 1 diabetes. N Engl J Med. 2017; 376(16): 1507-1516. doi:10.1056/NEJMoa1612836
- 140Januszewski AS, Velayutham V, Benitez-Aguirre PZ, et al. Optimal frequency of retinopathy screening in adolescents with type 1 diabetes-Markov modeling approach based on 30 years of data. Diabetes Care. 2022; 45: 2383-2390. doi:10.2337/dc22-0071
- 141Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. Jama. 2007; 298(8): 902-916. doi:10.1001/jama.298.8.902
- 142Mitchell P, Foran S. Guidelines for the Management of Diabetic Retinopathy Australian Diabetes Society for the Department of Health and Ageing; 2008. https://www.optometry.org.au/wp-content/uploads/Professional_support/Guidelines/nhmrc_diabetic_guidelines.pdf
- 143Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings, DRS report number 8. The diabetic retinopathy study research group. Ophthalmology. 1981; 88(7): 583-600.
- 144Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc. 1996; 94: 505-537.
- 145Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet (London, England). 2017; 389(10085): 2193-2203. doi:10.1016/s0140-6736(17)31193-5
- 146Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of Panretinal photocoagulation vs Intravitreous Ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018; 136(10): 1138-1148. doi:10.1001/jamaophthalmol.2018.3255
- 147Maguire MG, Liu D, Glassman AR, et al. Visual field changes over 5 years in patients treated with Panretinal photocoagulation or Ranibizumab for proliferative diabetic retinopathy. JAMA Ophthalmol. 2020; 138(3): 285-293. doi:10.1001/jamaophthalmol.2019.5939
- 148 Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372(13): 1193-1203. doi:10.1056/NEJMoa1414264
- 149Tan GS, Cheung N, Simo R, Cheung GC, Wong TY. Diabetic macular oedema. Lancet Diabetes Endocrinol. 2017; 5(2): 143-155. doi:10.1016/S2213-8587(16)30052-3
- 150Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014; 121(10): 1904-1914. doi:10.1016/j.ophtha.2014.04.024
- 151Šimunović M, Paradžik M, Škrabić R, Unić I, Bućan K, Škrabić V. Cataract as early ocular complication in children and adolescents with type 1 diabetes mellitus. Int J Endocrinol. 2018; 2018:6763586. doi:10.1155/2018/6763586
- 152Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019; 5(1): 41. doi:10.1038/s41572-019-0092-1
- 153Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017; 93(6): 1296-1313. doi:10.1016/j.neuron.2017.02.005
- 154Callaghan BC, Gallagher G, Fridman V, Feldman EL. Diabetic neuropathy: what does the future hold? Diabetologia. 2020; 63(5): 891-897. doi:10.1007/s00125-020-05085-9
- 155Jensen TS, Karlsson P, Gylfadottir SS, et al. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain. 2021; 144(6): 1632-1645. doi:10.1093/brain/awab079
- 156Akinci G, Savelieff MG, Gallagher G, Callaghan BC, Feldman EL. Diabetic neuropathy in children and youth: new and emerging risk factors. Pediatr Diabetes. 2021; 22(2): 132-147. doi:10.1111/pedi.13153
- 157Nelson D, Mah JK, Adams C, et al. Comparison of conventional and non-invasive techniques for the early identification of diabetic neuropathy in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2006; 7(6): 305-310. doi:10.1111/j.1399-5448.2006.00208.x
- 158Meh D, Denislic M. Subclinical neuropathy in type I diabetic children. Electroencephalogr Clin Neurophysiol. 1998; 109(3): 274-280. doi:10.1016/s0924-980x(98)00017-4
- 159Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh epidemiology of diabetes complications study. Diabetes. 1989; 38(11): 1456-1461. doi:10.2337/diab.38.11.1456
- 160Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications study. Diabetologia. 1996; 39(11): 1377-1384. doi:10.1007/s001250050586
- 161Jaiswal M, Divers J, Dabelea D, et al. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for diabetes in youth study. Diabetes Care. 2017; 40(9): 1226-1232. doi:10.2337/dc17-0179
- 162Pettitt DJ, Talton J, Dabelea D, et al. Prevalence of diabetes in U.S. youth in 2009: the SEARCH for diabetes in youth study. Diabetes Care. 2014; 37(2): 402-408. doi:10.2337/dc13-1838
- 163Hamman RF, Bell RA, Dabelea D, et al. The SEARCH for diabetes in youth study: rationale, findings, and future directions. Diabetes Care. 2014; 37(12): 3336-3344. doi:10.2337/dc14-0574
- 164Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. Jama. 2014; 311(17): 1778-1786. doi:10.1001/jama.2014.3201
- 165Risk factors for diabetic peripheral neuropathy in adolescents and Young adults with type 2 diabetes: results from the TODAY study. Diabetes Care. 2021;45(5):1065-1072. doi:10.2337/dc21-1074
- 166Pop-Busui R, Low PA, Waberski BH, et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the diabetes control and complications trial/epidemiology of diabetes interventions and complications study (DCCT/EDIC). Circulation. 2009; 119(22): 2886-2893. doi:10.1161/circulationaha.108.837369
- 167Vinik AI, Casellini C, Parson HK, Colberg SR, Nevoret ML. Cardiac autonomic neuropathy in diabetes: a predictor of Cardiometabolic events. Front Neurosci. 2018; 12: 591. doi:10.3389/fnins.2018.00591
- 168Jaiswal M, Urbina EM, Wadwa RP, et al. Reduced heart rate variability among youth with type 1 diabetes: the SEARCH CVD study. Diabetes Care. 2013; 36(1): 157-162. doi:10.2337/dc12-0463
- 169Jaiswal M, Divers J, Urbina EM, et al. Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: the SEARCH for diabetes in youth cohort study. Pediatr Diabetes. 2018; 19(4): 680-689. doi:10.1111/pedi.12633
- 170Tang M, Donaghue KC, Cho YH, Craig ME. Autonomic neuropathy in young people with type 1 diabetes: a systematic review. Pediatr Diabetes. 2013; 14(4): 239-248. doi:10.1111/pedi.12039
- 17113. Children and adolescents: standards of medical Care in Diabetes-2020. Diabetes Care. 2020; 43(Suppl 1): S163-s182. doi:10.2337/dc20-S013
- 172Donaghue KC, Marcovecchio ML, Wadwa RP, et al. ISPAD clinical practice consensus guidelines 2018: microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes. 2018; 19(Suppl 27): 262-274. doi:10.1111/pedi.12742
- 173Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017; 40(1): 136-154. doi:10.2337/dc16-2042
- 174Hirschfeld G, von Glischinski M, Blankenburg M, Zernikow B. Screening for peripheral neuropathies in children with diabetes: a systematic review. Pediatrics. 2014; 133(5): e1324-e1330. doi:10.1542/peds.2013-3645
- 175Braffett BH, Gubitosi-Klug RA, Albers JW, et al. Risk factors for diabetic peripheral neuropathy and cardiovascular autonomic neuropathy in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes. 2020; 69(5): 1000-1010. doi:10.2337/db19-1046
- 176Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994; 17(11): 1281-1289. doi:10.2337/diacare.17.11.1281
- 177Blankenburg M, Boekens H, Hechler T, et al. Reference values for quantitative sensory testing in children and adolescents: developmental and gender differences of somatosensory perception. Pain. 2010; 149(1): 76-88. doi:10.1016/j.pain.2010.01.011
- 178Blankenburg M, Kraemer N, Hirschfeld G, et al. Childhood diabetic neuropathy: functional impairment and non-invasive screening assessment. DiabetMed. 2012; 29(11): 1425-1432. doi:10.1111/j.1464-5491.2012.03685.x
- 179Bowling FL, Abbott CA, Harris WE, Atanasov S, Malik RA, Boulton AJ. A pocket-sized disposable device for testing the integrity of sensation in the outpatient setting. Diabet Med. 2012; 29(12): 1550-1552. doi:10.1111/j.1464-5491.2012.03730.x
- 180Höliner I, Haslinger V, Lütschg J, et al. Validity of the neurological examination in diagnosing diabetic peripheral neuropathy. Pediatr Neurol. 2013; 49(3): 171-177. doi:10.1016/j.pediatrneurol.2013.03.014
- 181Walter-Höliner I, Barbarini DS, Lütschg J, et al. High prevalence and incidence of diabetic peripheral neuropathy in children and adolescents with type 1 diabetes mellitus: results from a five-year prospective cohort study. Pediatr Neurol. 2018; 80: 51-60. doi:10.1016/j.pediatrneurol.2017.11.017
- 182Lee SS, Han HS, Kim H. A 5-yr follow-up nerve conduction study for the detection of subclinical diabetic neuropathy in children with newly diagnosed insulin-dependent diabetes mellitus. Pediatr Diabetes. 2010; 11(8): 521-528. doi:10.1111/j.1399-5448.2009.00636.x
- 183Hyllienmark L, Ludvigsson J, Brismar T. Normal values of nerve conduction in children and adolescents. Electroencephalogr Clin Neurophysiol. 1995; 97(5): 208-214. doi:10.1016/0013-4694(95)00092-d
- 184Agochukwu-Mmonu N, Pop-Busui R, Wessells H, Sarma AV. Autonomic neuropathy and urologic complications in diabetes. Auton Neurosci. 2020; 229:102736. doi:10.1016/j.autneu.2020.102736
- 185Eyre EL, Fisher JP, Smith EC, Wagenmakers AJ, Matyka KA. Ethnicity and long-term heart rate variability in children. Arch Dis Child. 2013; 98(4): 292-298. doi:10.1136/archdischild-2012-302266
- 186Selvarajah D, Kar D, Khunti K, et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol. 2019; 7(12): 938-948. doi:10.1016/s2213-8587(19)30081-6
- 187Krishnasamy S, Abell TL. Diabetic gastroparesis: principles and current trends in management. Diabetes Ther. 2018; 9(Suppl 1): 1-42. doi:10.1007/s13300-018-0454-9
- 188Sharma H, Lencioni M, Narendran P. Cardiovascular disease in type 1 diabetes. Cardiovasc Endocrinol Metab. 2019; 8: 28-34.
- 189Bjornstad P, Donaghue KC, Maahs DM. Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment? Lancet Diabetes Endocrinol. 2018; 6(10): 809-820. doi:10.1016/S2213-8587(18)30035-4
- 190Rawshani A, Sattar N, Franzén S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet (London, England). 2018; 392(10146): 477-486. doi:10.1016/s0140-6736(18)31506-x
- 191Giannopoulou EZ, Doundoulakis I, Antza C, et al. Subclinical arterial damage in children and adolescents with type 1 diabetes: a systematic review and meta-analysis. Pediatr Diabetes. 2019; 20(6): 668-677. doi:10.1111/pedi.12874
- 192Harrington J, Peña AS, Gent R, Hirte C, Couper J. Aortic intima media thickness is an early marker of atherosclerosis in children with type 1 diabetes mellitus. J Pediatr. 2010; 156(2): 237-241. doi:10.1016/j.jpeds.2009.08.036
- 193Järvisalo MJ, Putto-Laurila A, Jartti L, et al. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes. 2002; 51(2): 493-498. doi:10.2337/diabetes.51.2.493
- 194Järvisalo MJ, Raitakari M, Toikka JO, et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation. 2004; 109(14): 1750-1755. doi:10.1161/01.Cir.0000124725.46165.2c
- 195Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes. 2002; 51(8): 2637-2641.
- 196Maahs DM, Dabelea D, D'Agostino RB Jr, et al. Glucose control predicts 2-year change in lipid profile in youth with type 1 diabetes. J Pediatr. 2013; 162(1): 101-7 e1. doi:10.1016/j.jpeds.2012.06.006
- 197Guy J, Ogden L, Wadwa RP, et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for diabetes in youth case-control study. Diabetes Care. 2009; 32(3): 416-420. doi:10.2337/dc08-1775
- 198Jenkins AJ, Lyons TJ, Zheng D, et al. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care. 2003; 26(3): 810-818. doi:10.2337/diacare.26.3.810
- 199Idzior-Walus B, Mattock MB, Solnica B, Stevens L, Fuller JH. Factors associated with plasma lipids and lipoproteins in type 1 diabetes mellitus: the EURODIAB IDDM complications study. Diabet Med. 2001; 18(10): 786-796. doi:10.1046/j.0742-3071.2001.00571.x
- 200Edqvist J, Rawshani A, Adiels M, et al. BMI, mortality, and cardiovascular outcomes in type 1 diabetes: findings against an obesity paradox. Diabetes Care. 2019; 42(7): 1297-1304. doi:10.2337/dc18-1446
- 201Flokas ME, Zeymo A, Mete M, Anhalt H, Rother KI, Gourgari E. Overweight and obese children with optimal control in the T1D exchange registry: how are they different from lean children with optimal control? J Diabetes Complications. 2020; 34(4): 107513. doi:10.1016/j.jdiacomp.2019.107513
- 202Phelan H, Foster NC, Schwandt A, et al. Longitudinal trajectories of BMI z-score: an international comparison of 11,513 Australian, American and German/Austrian/Luxembourgian youth with type 1 diabetes. Pediatr Obes. 2020; 15(2):e12582. doi:10.1111/ijpo.12582
- 203Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, Fernández-Fernández C. Insulin resistance is a cardiovascular risk factor in humans. Diabet Metabol Syndrome Clin Res Rev. 2019; 13: 1449-1455.
- 204Miller RG, Costacou T, Orchard TJ. Risk factor modeling for cardiovascular disease in type 1 diabetes in the Pittsburgh epidemiology of diabetes complications (EDC) study: a comparison with the diabetes control and complications trial/epidemiology of diabetes interventions and complications study (DCCT/EDIC). Diabetes. 2019; 68(2): 409-419. doi:10.2337/db18-0515
- 205Marcovecchio ML, Dalton RN, Daneman D, et al. A new strategy for vascular complications in young people with type 1 diabetes mellitus. Nat Rev Endocrinol. 2019; 15(7): 429-435. doi:10.1038/s41574-019-0198-2
- 206Valerio G, Mozzillo E, Zito E, et al. Alcohol consumption or cigarette smoking and cardiovascular disease risk in youth with type 1 diabetes. Acta Diabetol. 2019; 56(12): 1315-1321. doi:10.1007/s00592-019-01415-5
- 207Bjornstad P, Pyle L, Nguyen N, et al. Achieving International Society for Pediatric and Adolescent Diabetes and American Diabetes Association clinical guidelines offers cardiorenal protection for youth with type 1 diabetes. Pediatr Diabetes. 2015; 16(1): 22-30. doi:10.1111/pedi.12252
- 208Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and Management of High Blood Pressure in children and adolescents. Pediatrics. 2017; 140(3):e20171904. doi:10.1542/peds.2017-1904
- 209Theodore RF, Broadbent J, Nagin D, et al. Childhood to early-midlife systolic blood pressure trajectories: early-life predictors, effect modifiers, and adult cardiovascular outcomes. Hypertension (Dallas, Tex: 1979). 2015; 66(6): 1108-1115. doi:10.1161/hypertensionaha.115.05831
- 210Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation. 2008; 117(25): 3171-3180. doi:10.1161/circulationaha.107.730366
- 211Soergel M, Kirschstein M, Busch C, et al. Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects. J Pediatr. 1997; 130(2): 178-184. doi:10.1016/s0022-3476(97)70340-8
- 212Siervo M, Lara J, Chowdhury S, Ashor A, Oggioni C, Mathers JC. Effects of the dietary approach to stop hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis. Br J Nutr. 2015; 113(1): 1-15. doi:10.1017/s0007114514003341
- 213Asghari G, Yuzbashian E, Mirmiran P, Hooshmand F, Najafi R, Azizi F. Dietary approaches to stop hypertension (DASH) dietary pattern is associated with reduced incidence of metabolic syndrome in children and adolescents. J Pediatr. 2016; 174: 178-184.e1. doi:10.1016/j.jpeds.2016.03.077
- 214Wells T, Frame V, Soffer B, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002; 42(8): 870-880. doi:10.1177/009127002401102786
- 215Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003; 16(10): 795-800. doi:10.1016/s0895-7061(03)00900-2
- 216Doran B, Guo Y, Xu J, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and nutrition examination survey III (NHANES-III). Circulation. 2014; 130(7): 546-553. doi:10.1161/circulationaha.114.010001
- 217Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration Cutpoints-a joint consensus statement from the European atherosclerosis society and European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2016; 62(7): 930-946. doi:10.1373/clinchem.2016.258897
- 218de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2014; 37(10): 2843-2863. doi:10.2337/dc14-1720
- 219Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011; 128((Suppl 5)): S213-S256. doi:10.1542/peds.2009-2107C
- 220Cadario F, Prodam F, Pasqualicchio S, et al. Lipid profile and nutritional intake in children and adolescents with type 1 diabetes improve after a structured dietician training to a Mediterranean-style diet. J Endocrinol Invest. 2012; 35(2): 160-168. doi:10.3275/7755
- 221Salem MA, AboElAsrar MA, Elbarbary NS, ElHilaly RA, Refaat YM. Is exercise a therapeutic tool for improvement of cardiovascular risk factors in adolescents with type 1 diabetes mellitus? A randomised controlled trial. Diabetol Metab Syndr. 2010; 2(1): 47. doi:10.1186/1758-5996-2-47
- 222Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (London, England). 2008; 371(9607): 117-125. doi:10.1016/s0140-6736(08)60104-x
- 223Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (London, England). 2003; 361(9374): 2005-2016. doi:10.1016/s0140-6736(03)13636-7
- 224Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004; 292(3): 331-337. doi:10.1001/jama.292.3.331
- 225Stein EA, Illingworth DR, Kwiterovich PO Jr, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999; 281(2): 137-144. doi:10.1001/jama.281.2.137
- 226Langslet G, Breazna A, Drogari E. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. J Clin lipidol. 2016; 10(5): 1153-1162.e3. doi:10.1016/j.jacl.2016.05.010
- 227Chiesa ST, Marcovecchio ML, Benitez-Aguirre P, et al. Vascular effects of ACE (angiotensin-converting enzyme) inhibitors and statins in adolescents with type 1 diabetes. Hypertension (Dallas, Tex: 1979). 2020; 76(6): 1734-1743. doi:10.1161/hypertensionaha.120.15721
